Plain-English translation of NCT06717919 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a new way to prepare donor livers before transplantation in patients with liver cancer (hepatocellular carcinoma). Instead of storing the donated liver in cold fluid the traditional way, researchers want to see if using a special machine called hypothermic oxygenated perfusion (HOPE) — which gently perfuses the liver with oxygen-rich cold fluid — can reduce the chance that cancer comes back after transplant.
About 15% of liver transplant patients develop cancer recurrence, and this risk depends on how well the donor liver is preserved. This trial exists to see whether the new perfusion technique can improve liver quality and lower the risk of cancer returning compared to the standard cold storage method.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to one of two groups: one group will receive a liver prepared using the new perfusion machine, and the other group will receive a liver prepared using the standard cold storage method. After your transplant, you will be monitored for at least 2 years with follow-up visits to check your health, survival, and whether cancer has returned. The study involves about 220 patients across multiple transplant centers worldwide and aims to follow everyone for at least 2 years after surgery.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Austria
Belgium